U.S. IVD And LDT For Autoimmune Diseases Market Research 2024-2030: Rising Awareness of Autoimmune Disorders Fuels Demand for Innovative Diagnostic Solutions Dublin, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The "U.S. IVD And LDT For Autoimmune Diseases Market Size, Share & Trends Analysis Report By Type (IVD, LDT), By Technology (Immunoassays, Clinical...

United Kingdom Ulcerative Colitis Market to Reach US$ 548.1 Million by 2031, Says CoherentMI Burlingame, July 30, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, United Kingdom Ulcerative Colitis Market was valued at US$ 421.3 Million in the year 2023 and is anticipated to...

Global Gut Microbiota Markets, Insights and Forecasts to 2031 - Key Players Danone, IFF, Ferring, and Nestle Focusing on R&D and Strategic Partnerships Dublin, July 12, 2024 (GLOBE NEWSWIRE) -- The "Gut Microbiota Market, By Product, By Application, By Disease Type, By End Users, By Distribution Channel: By Region - Market Size, Industry Dynamics,...

Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024 Event to highlight results from the clinical trial of BT-600, an orally administered drug-device combination in development for ulcerative colitis.

Biora Therapeutics Announces Positive Clinical Trial Results for BT-600 BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ability to deliver therapeutics directly to the colon